Loading...
Loading...
All product recalls affecting Arkansas.
Includes nationwide recalls (tagged “Nationwide”) and recalls with Arkansas in the distribution area.
Mitsubishi Fuso Truck of America, Inc. (MFTA) is recalling certain 2024 Rizon FEC7K (E16), FEC9K (E18), and 2025 FECXK (E18) trucks. The electric parking brake (EPB) actuator may use a spacer that is too big, resulting in excessive friction and overheated brake components.
Reports of delayed access to medication in automated dispensing cabinets because of the override/Add Item workflow.
Access Thyroglobulin reagent lot 439163 may generate erroneously high patient results. Falsely increased Access Thyroglobulin results may lead a physician to pursue unnecessary diagnostic imaging studies and/or inappropriate therapy adjustments in patients being monitored for residual or recurrent thyroid cancer.
Airstream, Inc. (Airstream) is recalling certain 2025 - 2026 Interstate motorhomes. The Parametric Special Module (PSM) may fail to lock the controls, allowing the awning to be extended during transit.
Prevost Car (US) Inc. (Prevost) is recalling certain 2025 X3-45 and 2025-2026 H3-45 coach buses. The fasteners securing the passenger seat back or the seat belt may be loose.
Knee implants contain incorrect labeling
Generations 67 and above of VITROS Ca Slides are experiencing an increased occurrence of Condition Code TH4-63J during calibration on VITROS XT 3400 and VITROS XT 7600 Systems, causing calibration failures that delay calcium test results and potentially impact patient management. The imaging reflectometer algorithm detects excessive "spikes" (imperfections) in slide images and generates the TH4-63J condition code when the threshold of 600 spikes is exceeded. Updated analysis revealed a 19-fold increase in failure rates from 0.0043% (2024 baseline) to 0.082% for Generation 67+ slides in 2025, with 100% of calibrator failures occurring at the lowest concentration level. This can result in delayed diagnosis and treatment of conditions such as hypercalcemic crisis, parathyroid disorders, and other calcium-related emergencies requiring urgent intervention.
Subpotent Drug
Sub-Potent Drug: Subpotent assay results during stability testing.
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Sub-Potent Drug: Subpotent assay results during stability testing.
Failed Dissolution Specifications.
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Subpotent Drug
Subpotent Drug
Potential for the manometer port being blocked rendering the manometer non-functional.
Subpotent Drug
Wire break(s) have occurred in rechargeable deep brain stimulation implantable pulse generators, implanted in the submuscular pectoral location. Wire breaks prevent successful stimulation, thus requiring device removal/replacement and users may experience high monopolar impedances, undesired sensation, loss of therapy, return of symptoms and/or Bluetooth connectivity challenges.
Resistance and difficulties could occur while closing the retaining clip locking mechanism, which is part of a burr hole cover kit, which is part of a Deep Brain Stimulation (DBS) system, which may lead to procedural delay, or lead-migration-which may require additional surgery.
Infusion pump module used with compatible pump infusion sets may perform outside the established performance ranges for flow rate and bolus accuracy, downstream and upstream occlusion time to alarm, and post-occlusion bolos volume.